Insulin‐like growth factors and diabetes

Diabetes/Metabolism Reviews

Volumn 8, Issue 3, 1992, Pages 229-257

  Bach, Leon A ^a   Rechler, Matthew M ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; INSULIN; SOMATOMEDIN BINDING PROTEIN;

ANIMAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; EXPERIMENTAL DIABETES MELLITUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; REVIEW; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONTROLLED STUDY; HUMAN TISSUE; KIDNEY DISEASE; MOLECULAR BIOLOGY; MONKEY; NONHUMAN; RAT; RETINOPATHY;

ANIMAL; CARRIER PROTEINS; CHILD, PRESCHOOL; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, INSULIN-DEPENDENT; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMAN; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2;

EID: 0027008753     PISSN: 07424221     EISSN: 10990895     Source Type: Journal    
DOI: 10.1002/dmr.5610080304     Document Type: Article

References (295)

1. The somatomedins: insulin‐like growth factors
2. Insulin‐like growth factors I, and II. Peptide messenger ribonucleic acid and gene structures, serum, and tissue concentrations
3. Insulin‐like growth factors I, and II
4. Revised nomenclature for the insulin‐like growth factor genes and transcripts
5. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro
6. Expression of insulin‐like growth factor I stimulates normal somatic growth in growth hormone‐deficient transgenic mice
7. Insulin‐like growth factor I stimulates growth in hypophysectomized rats
8. Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin‐like growth factor I
9. Growth promoting activity of IGF‐1 in the rat
10. Recombinant human insulin‐like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats
11. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action
12. Tissue distribution of insulin‐like growth factor I, and II messenger ribonucleic acid in the adult rat
13. Somatomedin‐C/insulin‐like growth factor‐I, and insulin‐like growth factor‐II mRNAs in rat fetal and adult tissues
14. Estimation of tissue concentrations of somatomedin C/insulin‐like growth factor I
15. Insulin‐like growth factors and cancer
16. Insulin‐like growth factor‐I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro
17. Analysis of insulin‐like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer
18. Short‐term metabolic effects of recombinant human insulinlike growth factor I in healthy adults
19. Diverse effects of insulin‐like growth factor I on glucose, lipid, and amino acid metabolism
20. Acute effects of insulin‐like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin
21. Actions of insulin‐like growth factors
22. Studies of acute effects of insulin‐like growth factors I, and II in human fat cells
23. Effects and binding of insulin‐like growth factor IGF‐I in the isolated soleus muscle of lean and obese mice: comparison with insulin
24. Acute and long‐term effects of insulin‐like growth factor I on glucose transporters in muscle cells. Translocation and biosynthesis
25. Chronic stimulation of glucose transporter gene expression in L6 myocytes mediated via the insulin‐like growth factor‐1 receptor
26. Development of the hormone‐sensitive glucose transport activity in differentiating 373–11 murine fibroblasts. Role of the two transporter species and their subcellular localization
27. Developmental regulation of insulin‐like growth factor‐I‐stimulated glucose transporter in rat brain astrocytes
28. Kidney function and size in normal subjects before and during growth hormone administration for one week
29. Effects of growth hormone and IGF‐I on renal function
30. Insulin‐like growth factor I increases glomerular filtration rate and renal plasma flow in man
31. Evidence that insulin‐like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats
32. Regulation by fasting of rat insulin‐like growth factor I, and its receptor. Effects on gene expression and binding
33. + transport
34. Influence of recombinant IGF‐I (somatomedin C) on sodium‐dependent phosphate transport in cultured renal epithelium
35. Dual control of cell growth by somatomedins and platelet‐derived growth factor
36. Insulin‐like growth factor I, and erythropoiesis
37. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin‐like growth factors
38. Vascular endothelium and diabetes mellitus
39. Effects of IGF‐I, and glucose on protein and proteoglycan synthesis by human fetal mesangial cells in culture
40. Regulation of insulin‐like growth factor I gene expression by growth hormone
41. Molecular cloning of rat insulin‐like growth factor I complementary deoxyribonucleic acids: differential messenger ribonucleic acid processing and regulation by growth hormone in extrahepatic tissues
42. Identification, characterization, and regulation of a rat complementary deoxyribonucleic acid which encodes insulin‐like growth factor‐I
43. Use of insulin‐like growth factor‐I measurements in diagnosis and in monitoring therapy. In Insulin‐like Growth Factors in Health and Disease, LeRoith D, Moderator
44. Serum levels of the low molecular weight form of insulin‐like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa
45. The decreased plasma concentration of insulin‐like growth factor I in protein‐restricted rats is not due to decreased numbers of growth hormone receptors on isolated hepatocytes
46. Dietary protein restriction decreases insulin‐like growth factor I independent of insulin and liver growth hormone binding
47. Role of the liver in regulating somatomedin activity: effects of streptozotocin diabetes and starvation on the synthesis and release of insulin‐like growth factor and its carrier protein by the isolated perfused rat liver
48. Regulation of insulin‐like growth factor I, and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues
49. Insulin‐like growth factors in the fed and fasted state
50. Sulphation factor (somatomedin activity) in experimental protein malnutrition in the rat
51. Dietary components that regulate serum somatomedin‐C in humans
52. Linear growth as a function of age at onset of puberty and sex steroid dosage: therapeutic implications
53. Effects of testosterone on somatomedin‐C concentrations in prepubertal boys
54. Effect of gonadectomy on growth hormone, IGF‐1 and sex steroids in children with complete and incomplete androgen insensitivity
55. Hormonal regulation of the peripubertal surge of insulin‐like growth factor‐I in the rat
56. Insulin regulates insulin‐like growth factor I mRNA in rat hepatocytes
57. The effect of acute and chronic insulin administration on insulin‐like growth factor I expression in the pituitary‐intact and hypophysectomised rat
58. Binding specificities and transducing function of the different molecular weight forms of insulin‐like growth factor‐II (IGF‐II) on IGF‐I receptors
59. Purification and characterization of an insulin‐like growth factor II variant from human plasma
60. Amino acid sequence of a variant pro‐form of insuli‐like growth factor II
61. Isolation of the human insulinlike growth factor genes: insulin‐like growth factor II, and insulin genes are contiguous
62. A growth‐deficiency phenotype in heterozygous mice carrying an insulin‐like growth factor II gene disrupted by targeting
63. Insulin‐like growth factor II: gene structure and expression into messenger RNA, and protein
64. IGF‐II receptors and IGF‐II‐stimulated glucose transport in human fat cells
65. “Spontaneous” differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin‐like growth factor‐II
66. Autonomous growth of a human neuroblastoma cell line is mediated by insulin‐like growth factor II
67. Insulin‐like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors
68. Synthesis and secretion of insulin‐like growth factor II by a leiomyosarcoma with associated hypoglycemia
69. The fetal rat binding protein for insulin‐like growth factors is expressed in the choroid plexus and cerebrospinal fluid of adult rats
70. Radioimmunological determination of insulin‐like growth factors I, and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia
71. Insulin‐like growth factor‐II gene expression in Wilms' tumour and embryonic tissues
72. Receptors for insulin and insulinlike growth factor‐I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells
73. Immunological relationships between receptors for insulin and insulinlike growth factor I. Evidence for structural heterogeneity of insulin‐like growth factor I receptors involving hybrids with insulin receptors
74. Insulinlike growth factor I receptor beta‐subunit heterogeneity. Evidence for hybrid tetramers composed of insulin‐like growth factor I, and insulin receptor heterodimers
75. Insulin‐like growth factor receptors
76. Structure of the insulin receptor substrate IRS‐1 defines a unique signal transduction protein
77. Insulin‐like growth factor‐I induces limited association of phosphatidylinositol 3‐kinase to its receptor
78. Association of phosphorylated insulin‐like growth factor‐I receptor with the SH2 domains of phosphatidylinositol 3‐kinase p85
79. The signalling potential of the receptors for insulin and insulin‐like growth factor I (IGF‐I) in 3T3‐L1 adipocytes: comparison of glucose transport activity, induction of oncogene c‐fos, glucose transporter mRNA, and DNA‐synthesis
80. Insulinlike growth factor I induces c‐fos messenger ribonucleic acid in L6 skeletal muscle cells
81. Insulinlike growth factor‐1 induces tyrosyl phosphorylation of nuclear proteins
82. Identification and characterization of insulin‐like growth factor receptors on adult rat cardiac myocytes: linkage to inositol 1,4,5‐trisphosphate formation
83. 1 phase of the cell cycle in BALB/c murine fibroblasts
84. Insulin‐like growth factor II receptor as a multifunctional binding protein
85. Biochemical evidence that the type II insulin‐like growth factor receptor is identical to the cation‐independent mannose 6‐phosphate receptor
86. Mannose 6‐phosphate/insulin‐like growth factor II receptor: distinct binding sites for mannose 6‐phosphate and insulin‐like growth factor II
87. Mannose 6‐phosphate/insulin‐like growth factor II receptor: the two types of ligands bind simultaneously to one receptor at different sites
88. Serum form of the rat insulin‐like growth factor II/mannose 6‐phosphate receptor is truncated in the carboxyl‐terminal domain
89. The nature and regulation of the receptors for insulin‐like growth factors
90. Insulin‐like growth factor II stimulates production of inositol trisphosphate in proximal tubular basolateral membranes from dog kidney
91. Binding of insulin‐like growth factor II, and multiplication‐stimulating activity‐stimulated phosphorylation in basolateral membranes from dog kidney
92. Parallel effects of insulin‐like growth factor‐II, and insulin on glucose metabolism of developing mouse embryonic limb buds in culture
93. Immunofluorescent localization of type II insulin‐like growth factor receptor in rat liver and hepatoma cells
94. Increase in the type 2 insulin‐like growth factor receptors in the rat kidney during compensatory growth
95. β‐Galactosidase decreases the binding affinity of the insulin‐like growth factor‐II/mannose‐6‐phosphate receptor for insulin‐like growth factor II
96. Possible direct linkage of insulin‐like growth factor‐II receptor with guanine nucleotide‐binding proteins
97. Regulation of transmembrane signal transduction of insulin‐like growth factor II by competence type growth factors or viral ras p21
98. Involvement of the plasmin system in dissociation of the insulin‐like growth factor‐binding protein complex
99. Isolation and characterization of a somatomedin‐binding protein from mid‐term human amniotic fluid
100. The role of insulin‐like growth factor binding proteins in controlling the expression of IGF actions
101. Phosphorylation of insulin‐like growth factor (IGF)‐binding protein in cell culture and in vivo: effects on affinity for IGF‐1
102. Insulin‐like growth factor binding protein‐1 is phosphorylated by cultured human endometrial stromal cells and multiple protein kinases in vitro
103. An insulin‐like growth factor (IGF) binding protein enhances the biologic response to IGF‐I
104. Discrete alterations of the insulin‐like growth factor I molecule which alter its affinity for insulin‐like growth factor‐binding proteins result in changes in bioactivity
105. Partial purification and characterization of a binding protein for insulinlike activity (ILAs) in human amniotic fluid: a possible inhibitor of insulin‐like activity
106. Insulin‐like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF‐I in cultured choriocarcinoma cells
107. Different tissue distribution and hormonal regulation of mRNAs encoding rat insulin‐like growth factor binding proteins rIGFBP‐1 and rIGFBP‐2
108. Diurnal rhythm of growth hormone‐independent binding protein for insulin‐like growth factors in human plasma
109. Nutrition and somatomedin. XXV. Regulation of insulin‐like growth factor binding protein 1 in primary cultures of normal rat hepatocytes
110. Insulin regulation of insulin‐like growth factor‐binding protein production in cultured HepG2 cells
111. Regulation of growth hormone‐independent insulin‐like growth factor‐binding protein (BP‐28) in cultured human fetal liver explants
112. Insulin rapidly inhibits insulin‐like growth factor binding protein‐1 gene expression in H4‐II‐E rat hepatoma cells
113. Insulin inhibits transcription of the human gene for insulin‐like growth factor‐binding protein‐1
114. Insulin differentially alters transcapillary movement of intravascular IGFBP‐1, IGFBP‐2 and endothelial cell IGF‐binding proteins in the rat heart
115. Metabolic regulation of the growth hormone independent insulin‐like growth factor binding protein in human plasma
116. Radioimmunoassay of a 26,000‐dalton plasma insulin‐like growth factor‐binding protein: control by nutritional variables
117. Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus
118. Prolonged exercise increases serum insulin‐like growth factor‐binding protein concentrations
119. Insulin regulates the serum levels of low molecular weight insulin‐like growth factor‐binding protein
120. Dose‐response characteristics for suppression of low molecular weight plasma insulin‐like growth factor‐binding protein by insulin
121. Insulin dependent regulation of IGFBP‐1
122. Insulin‐like growth factor‐binding protein‐1 modulates blood glucose levels
123. Insulin‐like growth factor‐binding protein‐1: a role in glucose counterregulation?
124. Transcriptional regulation of rat insulin‐like growth factor‐binding protein‐1 expression by growth hormone
125. Dexamethasone increases hepatic insulin‐like growth factor binding protein‐1 (IGFBP‐1) mRNA, and serum IGFBP‐1 concentrations in the rat
126. Dexamethasone stimulates transcription of the insulinlike growth factor binding protein‐1 (IGFBP‐1) gene in H4‐II‐E rat hepatoma cells
127. Gene expression of insulin‐like growth factors (IGFs), the type 1 IGF receptor, and IGF‐binding proteins in dexamethasone‐induced fetal growth retardation
128. Inhibitors of glucose uptake stimulate the production of insulinlike growth factor‐binding protein (IGFBP‐1) by human fetal liver
129. Divergent effects of phorbol esters and insulin on insulin‐like growth factor binding protein‐1 (IGFBP‐1) production and mRNA in rat H4IIE hepatoma cells
130. Nucleotide sequence and expression of a cDNA clone encoding a fetal rat binding protein for insulin‐like growth factors
131. Variables controlling the secretion of insulin‐like growth factor binding protein‐2 in normal human subjects
132. Two insulin‐like growth factor (IGF)‐binding proteins are responsible for the selective affinity for IGF‐II of cerebrospinal fluid binding proteins
133. Evaluation of the developmental and nutritional changes in porcine insulin‐like growth factor‐binding protein‐1 and ‐2 serum levels by immunoassay
134. Transcription of the insulin‐like growth factor binding protein‐2 gene is increased in neonatal and fasted adult rat liver
135. Regulation of binding proteins for insulin‐like growth factor (IGF) in humans
136. Molecular forms of serum insulin‐like growth factor (IGF)‐binding proteins in man: relationships with growth hormone and IGFs and physiological significance
137. Insulin‐like growth factor‐binding protein from human plasma: purification and characterization
138. Characterization of the acid‐labile subunit of the growth hormone‐dependent insulin‐like growth factor binding protein complex
139. Insulin‐like growth factor (IGF) and IGF‐binding proteins: comparison of human serum and lymph
140. Regulation of insulin‐like growth factor (IGF) binding proteins in transgenic mice with altered expression of growth hormone and IGF‐I
141. Radioimmunoassay of growth hormone‐dependent insulinlike growth factor binding protein in human plasma
142. Tissue distribution and regulation of insulin‐like growth factor (IGF)‐binding protein‐3 messenger ribonucleic acid (mRNA) in the rat: comparison with IGF‐I mRNA expression
143. Glycosaminoglycans inhibit formation of the 140 kDa insulin‐like growth factor‐binding protein complex
144. Evidence of enzymatic degradation of insulin‐like growth factor‐binding proteins in the 150 K complex during pregnancy
145. Maternal insulin‐like growth factor‐binding protein messenger ribonucleic acid during rat pregnancy
146. Insulin‐like growth factor binding protein‐3 (IGFBP‐3) is functionally normal in pregnancy serum
147. The induction of a specific protease for insulin‐like growth factor binding protein‐3 in the circulation during severe illness
148. Insulin‐like growth factor (IGF) binding to human fibroblast and glioblastoma cells: the modulating effect of cell released IGF binding proteins (IGFBPs)
149. Growth hormone‐dependent insulin‐like growth factor (IGF) binding protein both inhibits and potentiates IGF‐I‐stimulated DNA synthesis in human skin fibroblasts
150. Insulin‐like growth factor (IGF)‐binding protein‐3 blocks IGF‐I‐induced receptor down‐regulation and cell desensitization in cultured bovine fibroblasts
151. Isolation of an inhibitory insulin‐like growth factor (IGF) binding protein from bone cell‐conditioned medium: a potential local regulator of IGF action
152. Identification of a novel binding protein for insulin‐like growth factors in adult rat serum
153. Molecular cloning of the cDNAs encoding a novel insulin‐like growth factor‐binding protein from rat and human
154. Parathyroid hormone and parathyroid hormone‐related peptide stimulate insulin‐like growth factor‐binding protein secretion by rat osteoblast‐like cells through an adenosine 3′,5′‐monophosphate‐dependent mechanism
155. 3 differentially regulates the production of insulinlike growth factor I (IGF‐I) and IGF‐binding protein‐4 in mouse osteoblasts
156. Identification of five different insulin‐like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP‐5 in rat and human
157. Isolation from adult human serum of four insulinlike growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia
158. Molecular cloning of a new human insulin‐like growth factor binding protein
159. Isolation of a novel insulin‐like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF‐II in human bone
160. Purification and properties of a novel insulin‐like growth factor‐II binding protein from transformed human fibroblasts
161. An insulin‐like growth factor‐binding protein purified from medium conditioned by a human lung fibroblast cell line (HE[39]L) has a novel N‐terminal sequence
162. Human insulin‐like growth factor binding protein‐6 is O‐glycosylated
163. Is insulin‐like growth factor I associated with diabetic retinopathy?
164. Association of elevated IGF‐I levels with increased retinopathy in late‐onset diabetes
165. Serum insulin‐like growth factor I levels in adult diabetic patients: the effect of age
166. Insulin‐infusion‐pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels
167. Von Willebrand factor (VIII R:Ag), fibronectin, and insulin‐like growth factors I, and II in diabetic retinopathy and nephropathy
168. Progression of diabetic retinopathy and changes in serum insulin‐like growth factor I (IGF‐I) during continuous subcutaneous insulin infusion (CSII)
169. Sample size for clinical and biological research
170. Insulin‐like growth factors. Studies in diabetics with and without retinopathy
171. Growth hormone secretion in type I diabetes: a review
172. Effect of pubertal stage and recent blood glucose control on plasma somatomedin C in children with insulin‐dependent diabetes mellitus
173. 1 in type I diabetes
174. Relationships between growth factors (somatomedin‐C, and growth hormone) and body development, metabolic control, and retinal changes in children with IDDM
175. Somatomedin‐C/IGF‐I measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls
176. Effect of diabetes and its control on insulin‐like growth factors in the young subject with type I diabetes
177. Serum levels of insulinlike growth factor (IGF) and IGF binding protein in insulin‐dependent diabetics during an episode of severe metabolic decompensation and the recovery phase
178. Effect of glycemic control on serum insulinlike growth factors in diabetes mellitus
179. Factors related to renal haemodynamics in young type‐1 diabetes mellitus patients
180. Comparison of acid ethanol extraction and acid gel filtration prior to IGF‐I, and IGF‐II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF‐I as radioligand
181. Growth hormone secretory dynamics in streptozotocin diabetes: evidence of a role for endogenous circulating somatostatin
182. Growth restoration of insulin‐deficient diabetic rats by recombinant human insulin‐like growth factor I
183. Production of insulin‐like growth factor I, and its binding protein in rat hepatocytes cultured from diabetic and insulin‐treated diabetic rats
184. Nutrition and somatomedin. XIX. Molecular regulation of insulin‐like growth factor‐1 in streptozotocin‐diabetic rats
185. Regulation of start site usage in the leader exons of the rat insulin‐like growth factor‐I gene by development, fasting, and diabetes
186. Coordinate decrease of tissue insulinlike growth factor I posttranscriptional alternative mRNA transcripts in diabetes mellitus
187. Association between serum insulin, serum somatomedin and liver receptors for human growth hormone in streptozotocin diabetes
188. Low serum somatomedin C in insulin‐dependent diabetes: evidence for a postreceptor mechanism
189. Insulin‐like growth factor‐I (IGF‐I) and especially IGF‐I variants are anabolic in dexamethasone‐treated rats
190. Pituitary insulin‐like growth factor‐I content and gene expression in the streptozotocin‐diabetic rat: evidence for tissue‐specific regulation
191. Insulin‐like growth factor‐I, and ‐II messenger RNA expression in muscle, heart, and liver of streptozotocin‐diabetic swine
192. Relationship of insulin binding and insulin‐stimulated tyrosine kinase activity is altered in type II diabetes
193. IGF‐I‐stimulated glucose transport in human skeletal muscle and IGF‐I resistance in obesity and NIDDM
194. Altered placental insulin and insulin‐like growth factor‐I receptors in diabetes
195. Increased autophosphorylation of insulin‐like growth factor‐I, and insulin receptors in placentas of diabetic women
196. Antibodies to insulin‐like growth factor I receptors in diabetes and other disorders
197. Antireceptor antibodies as probes of insulinlike growth factor receptor structure
198. Experimental diabetes increases insulinlike growth factor I, and II receptor concentration and gene expression in kidney
199. Regulation of insulin‐like growth factor I receptors in diabetic mesangial cells
200. Insulin‐like growth factor‐I expression is not increased in the retina of diabetic BB/W‐rats
201. Insulin injection increases the level of serum receptors for transferrin and insulin‐like growth factor‐II/mannose‐6‐phosphate in intact rats
202. Circadian variation of GH‐independent IGF‐binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin?
203. Abnormal regulation of insulin‐like growth factor binding proteins in adolescents with insulin‐dependent diabetes
204. The growth hormone independent insulin‐like growth factor‐I binding protein BP‐28 is associated with serum insulin‐like growth factor‐I inhibitory bioactivity in adolescent insulin‐dependent diabetics
205. Regulation of low molecular weight insulin‐like growth factor binding proteins in experimental diabetes mellitus
206. Focal induction of IGF binding proteins in proximal tubules of diabetic rat kidney
207. Transcriptional regulation of insulin‐like growth factor binding protein 1 in diabetic rat liver
208. Differential expression of insulin‐like growth factor‐I, and insulin‐like growth factor binding protein‐1 in the diabetic rat
209. Nutrition and somatomedin: XXVII. Total and free IGF‐I, and IGF binding proteins in rats with streptozocin‐induced diabetes
210. Regulation of hepatic expression of IGF I, and fetal IGF binding protein mRNA in streptozotocin‐diabetic rats
211. Recombinant human insulin‐like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats
212. Differential expression of the insulin‐like growth factor binding proteins in spontaneously diabetic rats
213. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease
214. Protein glycation: its role in the changes induced by diabetes in the properties of the serum insulin‐like growth factor‐I binding proteins
215. Recombinant human insulin‐like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance
216. Acute response to recombinant insulin‐like growth factor I in a patient with Mendenhall's syndrome (Letter)
217. Acute metabolic effects and half‐lives of intravenously administered insulinlike growth factors I, and II in normal and hypophysectomized rats
218. Metabolic effects of IGF‐I, and insulin in spontaneously diabetic BB/W rats
219. Metabolic effects of IGF‐I in diabetic rats
220. Insulin‐like growth factor‐I in non‐insulin‐dependent diabetic monkeys: basal plasma concentrations and metabolic effects of exogenously administered biosynthetic hormone
221. Variables controlling the secretion of a somatomedin‐like peptide by cultured porcine smooth muscle cells
222. Neovascular growth factors
223. Expression of insulin and insulin‐like growth factor receptors and binding proteins by retinal pigment epithelium
224. Gene expression of the insulin‐like growth factors and their receptors in cultured human retinal pigment epithelial cells
225. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic orgin
226. Insulin‐like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells
227. The Houssay phenomenon in man. Recovery from retinopathy in a case of diabetes with Simmond's disease
228. Diabetes, diabetic angiopathy, and growth hormone
229. Role of growth hormone in diabetes mellitus
230. A follow‐up study of vascular disease in growth‐hormone‐deficient dwarfs with diabetes
231. Long‐term follow‐up of patients who underwent yttrium‐90 pituitary implantation for treatment of proliferative diabetic retinopathy
232. Insulin‐like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization
233. Circulating insulin‐like growth factor I in type 1 (insulin‐dependent) diabetic patients with retinopathy
234. Evidence for an insulin‐like growth factor autocrine‐paracrine system in the retinal photoreceptor‐pigment epithelial cell complex
235. Increased kidney size and glomerular filtration rate in early juvenile diabetes
236. Therapeutic interventions in nephropathy of IDDM
237. Long‐term prognosis in juvenile diabetes mellitus
238. The changing natural history of nephropathy in type I diabetes
239. Contribution of diabetes before puberty to development of microvascular complications in IDDM subjects
240. Microalbuminuria in diabetic children and adolescents and its relationship to puberty
241. Microalbuminuria in children with insulin‐dependent diabetes mellitus
242. Insulinlike growth factor‐1 is a progression factor for human mesangial cells
243. Prognostic implications of renal hypertrophy in diabetes mellitus
244. Evidence for the central role of glomerular growth promotors in the development of sclerosis
245. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin‐dependent diabetes
246. Focal expression of insulin‐like growth factor I in rat kidney collecting duct
247. Localization of IGF‐I in adult rats. Immunohistochemical studies
248. Growth hormone stimulates sequential induction of c‐myc and insulin‐like growth factor I expression in vivo
249. Mosaic evolution of the insulin‐like growth factors
250. Synthesis and release of insulinlike growth factor I by mesangial cells in culture
251. Synthesis and binding of insulin‐like growth factor I by human glomerular mesangial cells
252. Evidence that somatomedin‐C is degraded by the kidney and inhibits insulin degradation
253. Binding and degradation of insulin‐like growth factors I, and II by rat kidney membrane
254. Dual regulation of insulin‐like growth factor I expression during renal hypertrophy
255. Growth hormone stimulates IGF‐I gene expression in isolated rat renal collecting duct
256. Renal expression of IGF I in hypersomatotropic states
257. Insulin‐like growth factor I gene expression in isolated rat renal collecting duct is stimulated by epidermal growth factor
258. Distinct receptors for insulin‐like growth factor I in rat glomeruli and tubules
259. Distribution of IGF receptors in the plasma membrane of proximal tubular cells
260. Binding of insulin‐like growth factor‐I by glomerular endothelial and epithelial cells: further evidence for IGF‐I action in the renal glomerulus
261. Receptors for and effects of insulin and IGF‐I in rat glomerular mesangial cells
262. Studies on binding and mitogenic effect of insulin and insulin‐like growth factor I in glomerular mesangial cells
263. IGF‐I, and IGF binding proteins in diabetes‐related kidney growth
264. Immunological distribution of one form of insulin‐like growth factor (IGF)‐binding protein and IGF peptides in human fetal tissues
265. Secretion of insulin‐like growth factor I, and its binding proteins by collecting duct cells
266. A study of growth regulators of renal cortical tubular cells in the rabbit liver
267. Kidney tissue somatomedin C, and initial renal growth in diabetic and uninephrectomised rats
268. Somatostatin analogue administration prevents increase in kidney somatomedin C, and initial renal growth in diabetic and uninephrectomized rats
269. Kidney IGF‐I mRNA in initial renal hypertrophy in experimental diabetes mellitus
270. Effect of puberty on initial kidney growth and rise in kidney IGF‐1 in diabetic rats
271. Somatomedin C in the kidney of streptozotocin diabetic rats
272. Effect of alloxan diabetes on kidney growth in intact and castrated mice
273. Diabetes‐related kidney growth and IGF‐I accumulation in castrated rats
274. Six months sandostatin treatment in diabetic rats: effects on kidney growth and urinary albumin excretion
275. The effects of growth hormone deficiency on kidney growth and IGF‐I accumulation in diabetic rats
276. Insulin‐like growth factors: a role in growth hormone negative feedback and body weight regulation via brain
277. Kidney insulinlike growth factor‐I mRNA levels are increased in postpubertal diabetic rats
278. 3H‐thymidine uptake in diabetic and uninephrectomized rats
279. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients
280. Metabolism of glomerular basement membrane in normal, hypophysectomized, and growth‐hormone‐treated diabetic rats
281. Kidney function and glomerular permeability to macromolecules in early juvenile diabetes
282. Uridine triphosphate and RNA synthesis during diabetes‐induced renal growth
283. Glomerular filtration rate in streptozocin‐induced diabetic rats. Role of exchangeable sodium, vasoactive hormones and insulin therapy
284. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor‐1
285. Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor‐I. I. Relationship between increased glomerular size and mesangial sclerosis
286. Growth and maturation of children with insulin dependent diabetes
287. The role of insulin‐like growth factor I in growth of diabetic rats
288. Insulin, IGF‐I, and growth in diabetic rats (Letter)
289. Somatomedins and insulin in diabetic pregnancies: effects on fetal macrosomia in the human and rhesus monkey
290. Nonsuppressible insulin‐like activity and somatomedin C levels in normal pregnant women, in pregnant women with gestational diabetes, and in umbilical cord blood of mature and premature infants
291. Serum levels of somatomedins and somatomedin‐binding protein in pregnant women with type I or gestational diabetes and their infants
292. Insulin‐like growth factor 1 and its binding protein 1 during normal and diabetic pregnancies
293. Insulin‐like growth factors (IGF) I, and II in diabetic pregnancy: suppression of normal pregnancy‐induced rise of IGF‐I
294. Pathogenesis of NIDDM: a balanced overview
295. Therapeutic potential of insulinlike growth factor I